Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Clene Inc. Common Stock

CLNN

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Last trade $3.41
Day change -$0.25 (-6.83%)
Day range $3.37 – $3.76
Volume 98,822
Market cap $53M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$52.7M
Price / earnings
—
Price / book
-3.56×
Price / sales
221.45×
EV / sales
260.63×
EV / EBITDA
-3.13×

Profitability

Earnings per share
-$1.86
Return on assets
-121.07%
Return on equity
181.16%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-1.3×
Current ratio
0.85×
Quick ratio
0.84×
Cash ratio
0.58×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.61M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CLNN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$56K$90K$15K$77K$15K$27K$81K$91K
Cost of revenue$16K$36K$0$23K$0$0$20K$18K
Gross profit$40K$54K$15K$54K$15K$27K$61K$73K
Selling, general and administrative$1.94M$1.93M$1.75M$2.05M$2.15M$2.38M$2.66M$3.16M
Research and development$4.45M$3.47M$329K$5.5M$3.51M$3.51M$1.48M$5.57M
Total operating expenses$6.39M$5.4M$2.08M$7.55M$5.66M$5.89M$4.14M$8.73M
Operating income-$6.35M-$5.35M-$2.06M-$7.5M-$5.65M-$5.86M-$4.08M-$8.66M
Interest expense-$665K-$695K-$791K-$746K-$649K-$679K-$608K-$516K
Income before taxes$3.92M-$13.42M-$8.09M-$9.23M-$8.78M-$7.42M-$751K-$13.55M
Income taxes$0$0$0$0$0$0$0$0
Net income$3.92M-$13.42M-$8.09M-$9.23M-$8.78M-$7.42M-$751K-$13.55M
Net income attributable to common shareholders$3.92M-$13.42M-$8.09M-$9.23M-$8.78M-$7.42M-$751K-$13.55M
EBITDA-$6M-$4.99M-$1.71M-$7.14M-$5.28M-$5.5M-$3.67M-$8.25M
Basic earnings per share$0.30-$1.08-$0.69-$0.85-$0.85-$0.78-$0.09-$1.61
Diluted earnings per share$0.05-$1.08-$0.69-$0.85-$0.85-$0.78-$0.09-$1.61

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Clene Inc. (CLNN) Tops Q3 Earnings Estimates

Clene Inc. (CLNN) reported quarterly earnings of $0.05 per share, beating consensus estimates of a $0.46 loss, representing a +110.87% earnings surprise. However, the company missed revenue expectations with $0.06 million versus the consensus estimate, down 37.78%. The stock has underperformed the market by 35.8% year-to-date and carries a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

Clene Inc. (Nasdaq: CLNN) announced the submission of a New Drug Application (NDA) to the FDA in October 2026 seeking accelerated approval of CNM-Au8 for treating amyotrophic lateral sclerosis (ALS). The submission is based on neurofilament light chain biomarker data and clinical outcomes. The company plans to continue with a confirmatory Phase 3 RESTORE-ALS study while awaiting FDA review.

GlobeNewswire Inc.

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

Clene Inc. announced key 2026 milestones for its investigational ALS drug CNM-Au8, including an FDA Type C meeting by Q1 2026, NDA submission via accelerated pathway in Q2 2026, and potential PDUFA date in H2 2026. The company secured $28 million in funding with runway into Q4 2026, and plans to initiate a Phase 3 confirmatory trial later in 2026. CNM-Au8 has demonstrated prolonged survival benefits and favorable safety profile across over 800 treated ALS patients.

GlobeNewswire Inc.

Clene to Provide CNM-Au8® ALS Program Update

Clene Inc. will host an investor call and webcast on December 3, 2025, to provide an update on its CNM-Au8 program for treating amyotrophic lateral sclerosis (ALS). The company is a late clinical-stage biopharmaceutical firm focused on neurodegenerative disease treatments.

The Motley Fool

Clene Posts 70% Revenue Drop in Q2

Clene, a clinical-stage biopharmaceutical company, reported a net loss of $(0.78) per share in Q2 2025, with minimal revenue of $27,000. The company continues advancing its CNM-Au8 therapy for neurodegenerative diseases while managing tight cash resources.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 11, 20241-for-20reverse split